51
Participants
Start Date
December 31, 2009
Primary Completion Date
January 31, 2011
Study Completion Date
January 31, 2011
cetuximab
Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
lenalidomide
Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
Flinders Medical Centre, Dept. of Oncology, Bedford Park
UZ Antwerpen Dept. of Medical Oncology, Antwerp
ULB Erasme Service de Gastroenterologie, Brussels
Grand hôpital de Charleroi, Oncologie, Charleroi
Algemeen Ziekenhuis Maria Middelares, Ghent
Universitaire Ziekenhuis Gasthuisberg K.U. Leuven Gastroenterologie, Oncologie, Leuven
Centre Hospitalier Universitaire Sart Tilman Liège, Liège
Klinikum Oldenburg gGmbH Klinik für Innere Medizin II, Oldenburg
Azienda Osperdaliero Universitaria Riuniti Umberto I-GM Lancisi-G. Salesi di Ancona Clinica di Oncologia Medica, Ancona
Azienda Ospedaliera Universitaria San Martino Unità Operativa Oncologia Medica, Genova
Azienda Ospedaliera Niguarda Ca' Grande, Oncologia Medica Falck, Milan
Hospital Vall D'Hebron Servicio de Oncología. Unidad de ensayos clínicos, Barcelona
Hospital Universitario Marques de Valdecilla Servicio de Oncología, Santander
Hospital Clinico Universitario de Valencia Servicio de Oncologia, Valencia
Östra Sjukhuset Kirurgkliniken, Gothenburg
Karolinska University Hospital, Solna, Karolinska Institutet Dept of Oncology, Stockholm
Akademiska Sjukhuset Onkologkliniken, Uppsala
Lead Sponsor
Celgene Corporation
INDUSTRY